

Vaccine Highlights

Recommendations, schedules, and more

Editor's note: The information in Vaccine Highlights is current as of October 16, 2012.

The next ACIP meetings

A committee of 15 national experts, the Advisory Committee on Immunization Practices (ACIP) advises CDC on the appropriate use of vaccines. ACIP meets three times a year in Atlanta; meetings are open to the public. The next two meetings will be held on Oct. 24–25, 2012, and Feb. 20–21, 2013. For more information, visit www.cdc.gov/vaccines/acip/index.html.

ACIP periodically issues recommendations on the use of vaccines. Clinicians who vaccinate should have a current set for reference. Published in the *Morbidity and Mortality Weekly Report (MMWR)*, ACIP recommendations are easily available. Here are sources:

- Download them from links on IAC's website: www.immunize.org/acip.
- Download them from CDC's website: www.cdc.gov/vaccines/pubs/acip-list.htm.

Influenza vaccine news

On August 17, CDC published ACIP's 2012 influenza recommendations, "Prevention and Control of Influenza with Vaccines—United States, 2012–13 Influenza Season." The recommendations discuss the vaccination schedule for children age 6 months through 8 years; febrile seizures associated with administration of influenza and 13-valent pneumococcal conjugate (PCV-13) vaccines; and vaccination recommendations for people with a history of egg allergy. For a copy, see pages 613–618 of www.cdc.gov/mmwr/pdf/wk/mm6132.pdf.

On August 3, CDC's Health Alert Network (HAN) issued an official CDC Health Advisory titled "Increase in Influenza A H3N2v Virus Infections in Three U.S. States." The HAN document reports between July 12 and August 3, 2012, 16 cases of H3N2v were reported and confirmed by CDC. Each of the 16 cases involved contact with swine prior to illness onset. The advisory includes interim recommendations for the public and healthcare providers, and access to resources. To access the HAN document, go to www.bt.cdc.gov/HAN/han00325.asp.

Pneumococcal vaccine news

On Oct. 12, CDC published ACIP recommendations titled "Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions." The recommendations follow:

Adults with the conditions specified below who are eligible for pneumococcal vaccine should be vaccinated with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13; Pfizer) during their next pneumococcal vaccination opportunity.

For pneumococcal vaccine-naïve people

ACIP recommends that adults age 19 years and older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who have not previously received PCV13 or 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23; Merck), receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later. Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for adults age 19 through 64 years with functional or anatomic asplenia and for people with immunocompromising conditions. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose.

For people previously vaccinated with PPSV23

Adults age 19 years and older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who previously have received 1 or more doses of PPSV23 should be given a PCV13 dose 1 or more years after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.

To access the CDC recommendations, see pages 816–819 of *MMWR* at www.cdc.gov/mmwr/pdf/wk/mm6140.pdf. Or for the web text version, go to www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm.

Vaccine coverage 2011–2012

On Aug. 31, CDC published "National and State Vaccination Coverage Among Adolescents Aged 13–17 Years—United States, 2011." The National Immunization Survey-Teen (NIS-Teen) provides vaccination coverage estimates for teens age 13–17 years in the 50 states, District of Columbia, seven selected local areas, and U.S. Virgin Islands. Access NIS-Teen on pages 671–677 of www.cdc.gov/mmwr/pdf/wk/mm6134.pdf or go to www.cdc.gov/mmwr/preview/mmwrhtml/mm6134a3.htm.

Subscribe to IAC Express!

www.immunize.org/subscribe



Get weekly updates on vaccine information while it's still news!

All the news we publish in "Vaccine Highlights" will be sent by email to you every Tuesday. Free!

To sign up, visit

www.immunize.org/subscribe

At the same time, you'll be able to sign up to receive other free IAC publications!

New and updated VISs

The use of most Vaccine Information Statements (VISs) is mandated by federal law. Listed below are the dates of the most current VISs. Check your stock of VISs against this list. If you have outdated VISs, print current ones from IAC's website at www.immunize.org/vis. You'll find VISs in more than 30 languages.

DTaP/DTP.....	5/17/07	MMRV	5/21/10
Hepatitis A.....	10/25/11	PCV13	4/16/10
Hepatitis B	2/2/12	PPSV	10/6/09
Hib	12/16/98	Polio	11/8/11
HPV (Cervarix)....	5/3/11	Rabies	10/6/09
HPV (Gardasil)....	2/22/12	Rotavirus.....	12/6/10
Influenza (LAIV)	7/2/12	Shingles	10/6/09
Influenza (TIV)	7/2/12	Td/Tdap	1/24/12
Japan. enceph.	12/7/11	Typhoid	5/29/12
Meningococcal.	10/14/11	Varicella	3/13/08
MMR	4/20/12	Yellow fever	3/30/11

Multi-vaccine VIS9/18/08
(for 6 vaccines given to infants/children:
DTaP, IPV, Hib, HepB, PCV, RV)

For a ready-to-print version of this table for posting in your practice, go to www.immunize.org/catg.d/p2029.pdf.